Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events

Methods for item selection in industry-sponsored oncology clinical trials

Peter C. Trask, Amylou Dueck, Elisabeth Piault, Alicyn Campbell

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

As new cancer treatment regimens demonstrate increased potential to improve patients' survival, more focus is directed toward the quality of that extension of life and to obtaining additional information from patients regarding their experience with treatment. The utility of capturing patient-reported treatment-related symptoms to complement traditional clinician-rated symptomatic adverse event reporting is well-documented. The National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events is an item library aimed at capturing patient-reported symptoms to inform the patient perspective on a treatment's tolerability. The U.S. Food and Drug Administration has recommended using the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events in clinical trials. A practical guideline is needed to inform a priori selection of specific Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events items for use in any given industry-sponsored oncology clinical trial. Standardizing this selection process will foster systematic and consistent data collection as part of drug development and enhance our knowledge on how to use patient-relevant information as part of a treatment's risk/benefit assessment. This article presents methods and consensus recommendations for selecting specific Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events items to include in early-phase and late-phase oncology clinical trials.

Original languageEnglish (US)
Pages (from-to)616-623
Number of pages8
JournalClinical trials (London, England)
Volume15
Issue number6
DOIs
StatePublished - Dec 1 2018

Fingerprint

Terminology
Industry
Clinical Trials
Therapeutics
National Cancer Institute (U.S.)
United States Food and Drug Administration
Libraries
Patient Reported Outcome Measures
Quality of Life
Guidelines
Survival
Pharmaceutical Preparations
Neoplasms

Keywords

  • Clinical trials
  • Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events
  • recommendations

ASJC Scopus subject areas

  • Pharmacology

Cite this

Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events : Methods for item selection in industry-sponsored oncology clinical trials. / Trask, Peter C.; Dueck, Amylou; Piault, Elisabeth; Campbell, Alicyn.

In: Clinical trials (London, England), Vol. 15, No. 6, 01.12.2018, p. 616-623.

Research output: Contribution to journalArticle

@article{8554ea92c2044f83a6a5669284dd48db,
title = "Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events: Methods for item selection in industry-sponsored oncology clinical trials",
abstract = "As new cancer treatment regimens demonstrate increased potential to improve patients' survival, more focus is directed toward the quality of that extension of life and to obtaining additional information from patients regarding their experience with treatment. The utility of capturing patient-reported treatment-related symptoms to complement traditional clinician-rated symptomatic adverse event reporting is well-documented. The National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events is an item library aimed at capturing patient-reported symptoms to inform the patient perspective on a treatment's tolerability. The U.S. Food and Drug Administration has recommended using the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events in clinical trials. A practical guideline is needed to inform a priori selection of specific Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events items for use in any given industry-sponsored oncology clinical trial. Standardizing this selection process will foster systematic and consistent data collection as part of drug development and enhance our knowledge on how to use patient-relevant information as part of a treatment's risk/benefit assessment. This article presents methods and consensus recommendations for selecting specific Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events items to include in early-phase and late-phase oncology clinical trials.",
keywords = "Clinical trials, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, recommendations",
author = "Trask, {Peter C.} and Amylou Dueck and Elisabeth Piault and Alicyn Campbell",
year = "2018",
month = "12",
day = "1",
doi = "10.1177/1740774518799985",
language = "English (US)",
volume = "15",
pages = "616--623",
journal = "Clinical Trials",
issn = "1740-7745",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events

T2 - Methods for item selection in industry-sponsored oncology clinical trials

AU - Trask, Peter C.

AU - Dueck, Amylou

AU - Piault, Elisabeth

AU - Campbell, Alicyn

PY - 2018/12/1

Y1 - 2018/12/1

N2 - As new cancer treatment regimens demonstrate increased potential to improve patients' survival, more focus is directed toward the quality of that extension of life and to obtaining additional information from patients regarding their experience with treatment. The utility of capturing patient-reported treatment-related symptoms to complement traditional clinician-rated symptomatic adverse event reporting is well-documented. The National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events is an item library aimed at capturing patient-reported symptoms to inform the patient perspective on a treatment's tolerability. The U.S. Food and Drug Administration has recommended using the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events in clinical trials. A practical guideline is needed to inform a priori selection of specific Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events items for use in any given industry-sponsored oncology clinical trial. Standardizing this selection process will foster systematic and consistent data collection as part of drug development and enhance our knowledge on how to use patient-relevant information as part of a treatment's risk/benefit assessment. This article presents methods and consensus recommendations for selecting specific Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events items to include in early-phase and late-phase oncology clinical trials.

AB - As new cancer treatment regimens demonstrate increased potential to improve patients' survival, more focus is directed toward the quality of that extension of life and to obtaining additional information from patients regarding their experience with treatment. The utility of capturing patient-reported treatment-related symptoms to complement traditional clinician-rated symptomatic adverse event reporting is well-documented. The National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events is an item library aimed at capturing patient-reported symptoms to inform the patient perspective on a treatment's tolerability. The U.S. Food and Drug Administration has recommended using the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events in clinical trials. A practical guideline is needed to inform a priori selection of specific Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events items for use in any given industry-sponsored oncology clinical trial. Standardizing this selection process will foster systematic and consistent data collection as part of drug development and enhance our knowledge on how to use patient-relevant information as part of a treatment's risk/benefit assessment. This article presents methods and consensus recommendations for selecting specific Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events items to include in early-phase and late-phase oncology clinical trials.

KW - Clinical trials

KW - Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events

KW - recommendations

UR - http://www.scopus.com/inward/record.url?scp=85056280370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056280370&partnerID=8YFLogxK

U2 - 10.1177/1740774518799985

DO - 10.1177/1740774518799985

M3 - Article

VL - 15

SP - 616

EP - 623

JO - Clinical Trials

JF - Clinical Trials

SN - 1740-7745

IS - 6

ER -